Nu Skin Enterprises Updates Financial Guidance

  • Company Increases Fourth Quarter and 2012 Guidance in Advance of Annual Investor Day Meeting

    PROVO, Utah, Nov. 16, 2011 -- Nu Skin Enterprises, Inc. updated its fourth quarter 2011 and recently-issued 2012 financial guidance in advance of its annual investor day later today. The company increased its fourth quarter revenue guidance to $475 to $485 million, and earnings per share by $0.02 to $0.68 to $0.72. The company also increased 2012 revenue guidance to $1.80 to $1.83 billion with earnings per share of $2.82 to $2.92.

    "As we come to the conclusion of another record year, we continue to build momentum for the future," said Truman Hunt, president and chief executive officer. "We are revolutionizing the fight against aging through our ageLOC product pipeline, innovating in our direct selling channel, experiencing stellar growth in emerging markets, and continuing to drive shareholder value through improved efficiencies and increasing cash flow.

    "We are experiencing a very positive response from our distributor force following our global convention and the initial limited-time-offering of our new anti-aging products," Hunt continued. "The fourth quarter is shaping up even stronger than our initial forecast, and we have confirmed the amount of new products that will be shipped in January - allowing us to increase our guidance for the quarter and for 2012.

    "In short, we are succeeding because our strategy is sound and because we continue to improve our execution. We look forward to sharing our vision of the future with our shareholders at our annual investor day meeting later today," concluded Hunt.

    The annual investor day presentation will be held today at 9 a.m. at the Waldorf Astoria hotel in New York City. A webcast of the event, including the financial information to be presented, will be available at http://ir.nuskin.com . A replay of the webcast, along with accompanying slides, will be made available from the same location through Dec. 31.